Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preventing Pluripotent Cell Teratoma in Regenerative Medicine Applied to Hematology Disorders.

Stem cells translational medicine - 1 Feb 2017

Bedel Aurelie, Beliveau François, Lamrissi-Garcia Isabelle, Rousseau Benoit, Moranvillier Isabelle, Rucheton Benoit, Guyonnet-Dupérat Veronique, Cardinaud Bruno, de Verneuil Hubert, Moreau-Gaudry François, Dabernat Sandrine

Abstract excerpt

Iatrogenic tumorigenesis is a major limitation for the use of human induced pluripotent stem cells (hiPSCs) in hematology. The teratoma risk comes from the persistence of hiPSCs in differentiated cell populations. Our goal was to evaluate the best system to purge residual hiPSCs before graft without compromising hematopoietic repopulation capability. Teratoma risk after systemic injection of hiPSCs expressing the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 9
Share to Hematologic Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Naphthoquinones

Share to Regenerative Medicine

Share to Survivin

Share to Tacrolimus

Share to Teratoma

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 28191782
DOI: 10.5966/sctm.2016-0201
PMCID: PMC5442801

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preventing Pluripotent Cell Teratoma in Regenerative Medicine Applied to Hematology Disorders.PMID 28191782Read ↗

The safety of human pluripotent stem cells in clinical treatmentSemantic proximity Read ↗

Tumorigenicity risk of iPSCs <i>in vivo</i>: nip it in the budSemantic proximity Read ↗

Targeted biallelic integration of an inducible Caspase 9 suicide gene for safer cellular therapies prevents development of drug-resistant escapees in human iPSCsSemantic proximity Read ↗

Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration.Semantic proximity Read ↗

Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapiesSemantic proximity Read ↗

Generation of Engraftable Hematopoietic Stem Cells From Induced Pluripotent Stem Cells by Way of Teratoma FormationSemantic proximity Read ↗

Technological Overview of iPS Induction from Human Adult Somatic CellsSemantic proximity Read ↗

Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunitySemantic proximity Read ↗

Murine pluripotent stem cells that escape differentiation inside teratomas maintain pluripotencySemantic proximity Read ↗

Combination of immortalization and inducible death strategies to generate a human mesenchymal stromal cell line with controlled survivalSemantic proximity Read ↗

Introduction of OCT4 into human bone-marrow derived mesenchymal stromal cells generates putative iPS cells with the potential to differentiate into CD34+ hematopoietic progenitor cells ex vivoSemantic proximity Read ↗

Single OCT4 gene introduced into human bone-marrow derived mesenchymal stromal cells can generate putative iPS cells with the potential to differentiate into CD34+ hematopoietic progenitor cells ex vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.